Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler M, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Feb 27. pii: gfz023. doi: 10.1093/ndt/gfz023. [Epub ahead of print]

PMID:
30815678
2.

Performance of bleeding risk scores in dialysis patients.

Ocak G, Ramspek C, Rookmaaker MB, Blankestijn PJ, Verhaar MC, Bos WJW, Dekker FW, van Diepen M.

Nephrol Dial Transplant. 2019 Jan 4. doi: 10.1093/ndt/gfy387. [Epub ahead of print]

PMID:
30608543
3.

Lancet Countdown paper: what does it mean for nephrology?

Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlík I, Soler MJ, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jan 1;34(1):4-6. doi: 10.1093/ndt/gfy369. No abstract available.

PMID:
30496519
4.

Clinical evidence on haemodiafiltration.

Blankestijn PJ, Grooteman MP, Nube MJ, Bots ML.

Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii53-iii58. doi: 10.1093/ndt/gfy218.

5.

Role of Albumin Assay on Calcium Levels and Prescription of Phosphate Binders in Chronic Hemodialysis Patients.

de Roij van Zuijdewijn CLM, de Haseth DE, van Dam B, Bax WA, Grooteman MPC, Bots ML, Blankestijn PJ, Nubé MJ, van den Dorpel MA, Ter Wee PM, Penne EL.

Nephron. 2018;140(3):211-217. doi: 10.1159/000492238. Epub 2018 Sep 13.

6.

Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.

Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, Garcia-Fernandez N, Golay X, Gordon I, Grenier N, Hockings PD, Jensen JD, Joles JA, Kalra PA, Krämer BK, Mark PB, Mendichovszky IA, Nikolic O, Odudu A, Ong ACM, Ortiz A, Pruijm M, Remuzzi G, Rørvik J, de Seigneux S, Simms RJ, Slatinska J, Summers P, Taal MW, Thoeny HC, Vallée JP, Wolf M, Caroli A, Sourbron S.

Nephrol Dial Transplant. 2018 Sep 1;33(suppl_2):ii4-ii14. doi: 10.1093/ndt/gfy152.

7.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.

Zoccali C, Arici M, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G.

Clin Kidney J. 2018 Aug;11(4):437-442. doi: 10.1093/ckj/sfy064. Epub 2018 Jul 31.

8.

Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension.

Van Der Sande NGC, Blankestijn PJ, Visseren FLJ, Beeftink MM, Voskuil M, Westerink J, Bots ML, Spiering W.

J Hypertens. 2019 Feb;37(2):398-405. doi: 10.1097/HJH.0000000000001885.

PMID:
30074565
9.

Risk Factors for Prognosis in Patients With Severely Decreased GFR.

Evans M, Grams ME, Sang Y, Astor BC, Blankestijn PJ, Brunskill NJ, Collins JF, Kalra PA, Kovesdy CP, Levin A, Mark PB, Moranne O, Rao P, Rios PG, Schneider MP, Shalev V, Zhang H, Chang AR, Gansevoort RT, Matsushita K, Zhang L, Eckardt KU, Hemmelgarn B, Wheeler DC.

Kidney Int Rep. 2018 Jan 11;3(3):625-637. doi: 10.1016/j.ekir.2018.01.002. eCollection 2018 May. Erratum in: Kidney Int Rep. 2018 Aug 30;3(6):1506.

10.

Renal denervation in uncontrolled hypertension: the story continues to unfold.

Blankestijn PJ, Bots ML.

Lancet. 2018 Jun 9;391(10137):2300-2302. doi: 10.1016/S0140-6736(18)31112-7. Epub 2018 May 23. No abstract available.

PMID:
29803591
11.

ERA-EDTA invests in transformation to greener health care.

Blankestijn PJ, Arici M, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G, Zoccali C.

Nephrol Dial Transplant. 2018 Jun 1;33(6):901-903. doi: 10.1093/ndt/gfy092. No abstract available.

PMID:
29800317
12.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council.

Zoccali C, Arici M, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Malyszko J, Massy Z, Rychlík I, Spasovski G.

Nephrol Dial Transplant. 2018 Jul 1;33(7):1077-1082. doi: 10.1093/ndt/gfy173.

PMID:
29796635
13.

Long-term clinical parameters after switching to nocturnal haemodialysis: a Dutch propensity-score-matched cohort study comparing patients on nocturnal haemodialysis with patients on three-times-a-week haemodialysis/haemodiafiltration.

Jansz TT, Özyilmaz A, Grooteman MPC, Hoekstra T, Romijn M, Blankestijn PJ, Bots ML, van Jaarsveld BC.

BMJ Open. 2018 Mar 8;8(3):e019900. doi: 10.1136/bmjopen-2017-019900.

14.

Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C; Conference Participants .

Eur Heart J. 2018 Jun 21;39(24):2314-2325. doi: 10.1093/eurheartj/ehy060. No abstract available.

15.

Left ventricular geometric patterns in end-stage kidney disease: Determinants and course over time.

Nubé MJ, Hoekstra T, Doganer V, Bots ML, Blankestijn PJ, van den Dorpel M, Kamp O, Ter Wee PM, de Roij van Zuijdewijn CLM, Grooteman MPC.

Hemodial Int. 2018 Jul;22(3):359-368. doi: 10.1111/hdi.12644. Epub 2018 Feb 20.

PMID:
29461006
16.

Letter on 'European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis'.

Mark PB, Dekkers I, Blankestijn PJ, Leiner T, Roditi G.

J Eur Acad Dermatol Venereol. 2018 Feb;32(2):e84-e85. doi: 10.1111/jdv.14774. Epub 2018 Jan 23. No abstract available.

PMID:
29283443
17.

Achieving high convection volumes in postdilution online hemodiafiltration: a prospective multicenter study.

de Roij van Zuijdewijn CLM, Chapdelaine I, Nubé MJ, Blankestijn PJ, Bots ML, Konings CJAM, Kremer Hovinga TK, Molenaar FM, van der Weerd NC, Grooteman MPC.

Clin Kidney J. 2017 Dec;10(6):804-812. doi: 10.1093/ckj/sfw140. Epub 2017 Feb 15.

18.

Hypertension: Device therapy for uncontrolled hypertension: new approaches to an old problem.

Blankestijn PJ, Bots ML.

Nat Rev Nephrol. 2017 Nov 15;13(12):725-726. doi: 10.1038/nrneph.2017.150. No abstract available.

PMID:
29138517
19.

Modified dixon-based renal dynamic contrast-enhanced MRI facilitates automated registration and perfusion analysis.

de Boer A, Leiner T, Vink EE, Blankestijn PJ, van den Berg CAT.

Magn Reson Med. 2018 Jul;80(1):66-76. doi: 10.1002/mrm.26999. Epub 2017 Nov 13.

20.

Renal safety of catheter-based renal denervation: systematic review and meta-analysis.

Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, Bolignano D, Zoccali C, Blankestijn PJ.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1440-1447. doi: 10.1093/ndt/gfx088. Review.

PMID:
29059396
21.

Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis.

Persu A, Gordin D, Jacobs L, Thijs L, Bots ML, Spiering W, Miroslawska A, Spaak J, Rosa J, de Jong MR, Berra E, Fadl Elmula FEM, Wuerzner G, Taylor AHM, Olszanecka A, Czarnecka D, Mark PB, Burnier M, Renkin J, Kjeldsen SE, Widimský J, Elvan A, Kahan T, Steigen TK, Blankestijn PJ, Tikkanen I, Staessen JA; European Network COordinating research on Renal Denervation (ENCOReD).

J Hypertens. 2018 Feb;36(2):221-229. doi: 10.1097/HJH.0000000000001582.

PMID:
29045339
22.

Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension.

de Beus E, de Jager RL, Beeftink MM, Sanders MF, Spiering W, Vonken EJ, Voskuil M, Bots ML, Blankestijn PJ; SYMPATHY study group.

J Clin Hypertens (Greenwich). 2017 Nov;19(11):1125-1133. doi: 10.1111/jch.13085. Epub 2017 Sep 19.

23.

Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.

de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, Blankestijn PJ.

BMJ Open. 2017 Sep 6;7(9):e016692. doi: 10.1136/bmjopen-2017-016692.

24.

Sympathomodulatory effects of sodium-glucose transporter-2 inhibitors in the kidneys and beyond.

Blankestijn PJ, Wanner C, Grassi G.

J Hypertens. 2017 Oct;35(10):1966-1967. doi: 10.1097/HJH.0000000000001454. No abstract available.

PMID:
28858200
25.

Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.

de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY investigators.

Br J Clin Pharmacol. 2018 Jan;84(1):18-24. doi: 10.1111/bcp.13402. Epub 2017 Oct 10.

26.

Does renal denervation lower sympathetic activity?

Blankestijn PJ.

Nephrol Dial Transplant. 2017 Aug 1;32(8):1265-1267. doi: 10.1093/ndt/gfx217. No abstract available.

PMID:
28810725
27.

Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease.

van der Sande NGC, de Beus E, Bots ML, Voskuil M, Blankestijn PJ, Visseren F, Spiering W; SMART study group.

J Hypertens. 2018 Jan;36(1):143-150. doi: 10.1097/HJH.0000000000001494.

PMID:
28763342
28.

Quality of life as indicator of poor outcome in hemodialysis: relation with mortality in different age groups.

van Loon IN, Bots ML, Boereboom FTJ, Grooteman MPC, Blankestijn PJ, van den Dorpel MA, Nubé MJ, Ter Wee PM, Verhaar MC, Hamaker ME.

BMC Nephrol. 2017 Jul 6;18(1):217. doi: 10.1186/s12882-017-0621-7.

29.

Catheter-based renal denervation as therapy for chronic severe kidney-related pain.

de Jager RL, Casteleijn NF, de Beus E, Bots ML, Vonken EE, Gansevoort RT, Blankestijn PJ.

Nephrol Dial Transplant. 2018 Apr 1;33(4):614-619. doi: 10.1093/ndt/gfx086.

PMID:
28645206
30.

Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients.

van der Sande NGC, Visseren FLJ, van der Graaf Y, Nathoe HM, de Borst GJ, Leiner T, Blankestijn PJ; SMART Study Group.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):921-928. doi: 10.2215/CJN.08990816. Epub 2017 May 9.

31.

Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Mahfoud F, Schmieder RE, Azizi M, Pathak A, Sievert H, Tsioufis C, Zeller T, Bertog S, Blankestijn PJ, Böhm M, Burnier M, Chatellier G, Durand Zaleski I, Ewen S, Grassi G, Joner M, Kjeldsen SE, Lobo MD, Lotan C, Lüscher TF, Parati G, Rossignol P, Ruilope L, Sharif F, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W.

Eur Heart J. 2017 Nov 21;38(44):3272-3281. doi: 10.1093/eurheartj/ehx215. No abstract available.

32.

Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension.

Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, Voskuil M, Spiering W.

Hypertension. 2017 May;69(5):927-932. doi: 10.1161/HYPERTENSIONAHA.116.08793. Epub 2017 Apr 3.

PMID:
28373591
33.

The importance of considering competing treatment affecting prognosis in the evaluation of therapy in trials: the example of renal transplantation in hemodialysis trials.

Hazelbag CM, Peters SAE, Blankestijn PJ, Bots ML, Canaud B, Davenport A, Grooteman MPC, Kircelli F, Locatelli F, Maduell F, Morena M, Nubé MJ, Ok E, Torres F, Hoes AW, Groenwold RHH; HDF Pooling Project investigators.

Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii31-ii39. doi: 10.1093/ndt/gfw458.

PMID:
28339826
34.

Corrigendum: A closer look at the trajectory of physical functioning in chronic hemodialysis.

van Loon I, Hamaker ME, Boereboom FTJ, Grooteman MPC, Blankestijn PJ, van den Dorpel RMA, Nubé MJ, Ter Wee PM, Verhaar MC, Bots ML.

Age Ageing. 2018 Mar 1;47(2):320. doi: 10.1093/ageing/afx040. No abstract available.

PMID:
28338938
35.

Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure.

Beeftink MM, Spiering W, De Jong MR, Doevendans PA, Blankestijn PJ, Elvan A, Heeg JE, Bots ML, Voskuil M.

J Clin Hypertens (Greenwich). 2017 Apr;19(4):371-378. doi: 10.1111/jch.12989. Epub 2017 Mar 14.

36.

Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography.

Sanders MF, van Doormaal PJ, Beeftink MMA, Bots ML, Fadl Elmula FEM, Habets J, Hammer F, Hoffmann P, Jacobs L, Mark PB, Persu A, Renkin J, Roditi G, Spiering W, Staessen JA, Taylor AH, Verloop WL, Vink EE, Vonken EJ, Voskuil M, Leiner T, Blankestijn PJ; European Network COordinating research on Renal Denervation (ENCOReD) Consortium.

Eur Radiol. 2017 Sep;27(9):3934-3941. doi: 10.1007/s00330-017-4770-7. Epub 2017 Mar 7.

37.

Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.

de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY Investigators.

Hypertension. 2017 Apr;69(4):678-684. doi: 10.1161/HYPERTENSIONAHA.116.08818.

PMID:
28264922
38.

Changes in Cardiac Output and Perfusion during Hemodialysis and Hemodiafiltration Treatments Determined by Cardiac Magnetic Resonance Imaging.

Blankestijn PJ, Davenport A.

J Am Soc Nephrol. 2017 Apr;28(4):1013-1015. doi: 10.1681/ASN.2016111257. Epub 2017 Feb 9. No abstract available.

39.

A closer look at the trajectory of physical functioning in chronic hemodialysis.

van Loon I, Hamaker ME, Boereboom FTJ, Grooteman MPC, Blankestijn PJ, van den Dorpel RMA, Nubé MJ, Ter Wee PM, Verhaar MC, Bots ML.

Age Ageing. 2017 Jul 1;46(4):594-599. doi: 10.1093/ageing/afx006.

PMID:
28164208
40.

Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease.

Casteleijn NF, van Gastel MD, Blankestijn PJ, Drenth JP, de Jager RL, Leliveld AM, Stellema R, Wolff AP, Groen GJ, Gansevoort RT; DIPAK Consortium.

Kidney Int. 2017 Apr;91(4):972-981. doi: 10.1016/j.kint.2016.12.007. Epub 2017 Jan 31.

PMID:
28159317
41.

High ratios of kidney function to kidney size are related to mortality and kidney function decline in high-risk patients.

van der Sande NG, Blankestijn PJ, Leiner T, van der Graaf Y, de Borst GJ, Cramer MJ, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2017 Jun;24(9):926-933. doi: 10.1177/2047487317690950. Epub 2017 Jan 25.

PMID:
28121180
42.

Uremic Solutes in Chronic Kidney Disease and Their Role in Progression.

van den Brand JA, Mutsaers HA, van Zuilen AD, Blankestijn PJ, van den Broek PH, Russel FG, Masereeuw R, Wetzels JF.

PLoS One. 2016 Dec 29;11(12):e0168117. doi: 10.1371/journal.pone.0168117. eCollection 2016.

43.

Mortality reduction by post-dilution online-haemodiafiltration: a cause-specific analysis.

Nubé MJ, Peters SAE, Blankestijn PJ, Canaud B, Davenport A, Grooteman MPC, Asci G, Locatelli F, Maduell F, Morena M, Ok E, Torres F, Bots ML; HDF Pooling Project investigators.

Nephrol Dial Transplant. 2017 Mar 1;32(3):548-555. doi: 10.1093/ndt/gfw381.

PMID:
28025382
44.

Are There Any Downsides, Barriers, or Challenges in Delivering Hemodiafiltration in Everyday Clinical Practice?

Blankestijn PJ, Grooteman M, Nube M.

Contrib Nephrol. 2017;189:30-35. Epub 2016 Dec 12. Review.

PMID:
27951547
45.

[Renal denervation as treatment option for hypertension].

Blankestijn PJ, Bots ML.

Ned Tijdschr Geneeskd. 2016;160:D629. Review. Dutch.

PMID:
27781967
46.

Renal Denervation in a Real Life Setting: A Gradual Decrease in Home Blood Pressure.

Beeftink MM, Spiering W, Bots ML, Verloop WL, De Jager RL, Sanders MF, Vonken EJ, Blankestijn PJ, Voskuil M.

PLoS One. 2016 Sep 15;11(9):e0162251. doi: 10.1371/journal.pone.0162251. eCollection 2016.

47.

Anatomical and procedural determinants of catheter-based renal denervation.

Ewen S, Ukena C, Lüscher TF, Bergmann M, Blankestijn PJ, Blessing E, Cremers B, Dörr O, Hering D, Kaiser L, Nef H, Noory E, Schlaich M, Sharif F, Sudano I, Vogel B, Voskuil M, Zeller T, Tzafriri AR, Edelman ER, Lauder L, Scheller B, Böhm M, Mahfoud F.

Cardiovasc Revasc Med. 2016 Oct - Nov;17(7):474-479. doi: 10.1016/j.carrev.2016.08.004. Epub 2016 Aug 20.

PMID:
27617388
48.

Why choose high volume online post-dilution hemodiafiltration?

Basile C, Davenport A, Blankestijn PJ.

J Nephrol. 2017 Apr;30(2):181-186. doi: 10.1007/s40620-016-0343-0. Epub 2016 Sep 1. Review.

PMID:
27586123
49.

Reconciling and Closing the Loop Between Evidence-Based and Practice-Based Medicine: The Case for Hemodiafiltration.

Canaud B, Blankestijn PJ, Davenport A, Bots ML.

Am J Kidney Dis. 2016 Aug;68(2):176-179. doi: 10.1053/j.ajkd.2016.05.006. No abstract available.

PMID:
27477357
50.

Chronic Kidney Disease As a Potential Indication for Renal Denervation.

Sanders MF, Blankestijn PJ.

Front Physiol. 2016 Jun 8;7:220. doi: 10.3389/fphys.2016.00220. eCollection 2016. Review.

Supplemental Content

Loading ...
Support Center